The first and only approved treatment for osteoarthritis knee pain utilizing extended-release microsphere technology
ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) is a novel formulation composed of triamcinolone acetonide (TA) embedded in a biodegradable PLGA matrix that extends residence time in the joint.1,2
Microspheres in the knee
- After injection of ZILRETTA, microspheres localize on the synovium, away from the articular cartilage3
- When in contact with synovial fluid, TA in the microsphere slowly dissolves and is released as a liquid1
- After TA is released over time, microspheres degrade and are metabolized to C02 and H201
Learn more about the microsphere technology of ZILRETTA
ZILRETTA is not interchangeable with other formulations of injectable triamcinolone acetonide.